WUXI BIO(02269),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02269 WUXI BIO

Not Yet Opened 04-27 16:08:30

33.280

-0.240

-0.72%

High33.700	Low33.060	Vol15.38M
Open33.600	D1 Closing33.520	Amplitude1.91%
Mkt Cap137.71B	Tradable Cap137.71B	Total Shares4.14B
T/O511.94M	T/O Rate0.37%	Tradable Shares4.14B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02269","market":"HK","secType":"STK","nameCN":"WUXI BIO","latestPrice":33.28,"timestamp":1777277310004,"preClose":33.52,"halted":0,"volume":15380380,"delay":0,"changeRate":-0.007159904534606264,"floatShares":4138000000,"shares":4138000000,"eps":1.3323824211541027,"marketStatus":"Not Yet Opened","change":-0.24,"latestTime":"04-27 16:08:30","open":33.6,"high":33.7,"low":33.06,"amount":511944807,"amplitude":0.019093,"askPrice":33.28,"askSize":5000,"bidPrice":33.26,"bidSize":13000,"shortable":3,"etf":0,"ttmEps":1.3323824211541027,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1777339800000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1497283200000,"exchange":"SEHK","adjPreClose":33.52,"openAndCloseTimeList":[[1777253400000,1777262400000],[1777266000000,1777276800000]],"volumeRatio":0.763431,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"WXB.HK","impliedVol":0.4647,"impliedVolPercentile":0.1545},"requestUrl":"/m/hq/s/02269/tweets","defaultTab":"tweets","newsList":[{"id":"2629984494","title":"WuXi Biologics completes structure of Chengdu microbial manufacturing site ahead of 2026 GMP release","url":"https://stock-news.laohu8.com/highlight/detail?id=2629984494","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629984494?lang=en_us&edition=fundamental","pubTime":"2026-04-24 21:14","pubTimestamp":1777036496,"startTime":"0","endTime":"0","summary":"WuXi Biologics completed structure of microbial commercial manufacturing site in Chengdu, targeting GMP release by end-2026.Facility spans about 95,000 square meters in Wenjiang District, designed for commercial drug substance and drug product output for microbial-derived biologics.Site will install 15,000 L fermentation capacity, supporting up to 110 drug substance batches per year.Drug product buildout includes China’s first dual-chamber lyophilization line, targeting capacity above 10 million vials per year.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuxi Biologics  Inc. published the original content used to generate this news brief on April 24, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nNDL1lPY3T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2039709279.SGD","LU0052750758.USD","LU3063872942.SGD","LU0348825331.USD","LU0516423091.SGD","LU0181495838.USD","LU0516422952.EUR","LU0348735423.USD","LU0456846285.SGD","LU0516422440.USD","LU1242518857.USD","02269","IE00B0JY6N72.USD","LU1720050803.USD","LU0326950275.SGD","LU0359202008.SGD","LU0043850808.USD","LU0359201612.USD","BK1610","LU0417516738.SGD","LU0051755006.USD","LU1242518931.SGD","LU0979878070.USD","LU1688375341.USD","LU0572944931.SGD","LU0327786744.USD","LU0516423174.USD","LU0708995583.HKD","LU0307460666.USD","LU1794554557.SGD","BK1589","BK1141","LU0456827905.SGD","LU0417516902.SGD","LU0039217434.USD","LU0588546209.SGD","LU0823426480.USD","LU0516422366.SGD","LU0823426308.USD","LU1880383366.USD","LU0819121731.USD","BK1576","LU0856984785.SGD","BK1521","LU0320764599.SGD","LU0140636845.USD","SG9999002562.SGD","SG9999002463.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629819965","title":"WuXi XDC publishes 2025 annual report","url":"https://stock-news.laohu8.com/highlight/detail?id=2629819965","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629819965?lang=en_us&edition=fundamental","pubTime":"2026-04-24 16:47","pubTimestamp":1777020420,"startTime":"0","endTime":"0","summary":"WuXi XDC published its 2025 annual report, highlighting continued rapid expansion in bioconjugates CRDMO services.Business scale widened, with integrated iCMC projects rising to 252 as of Dec. 31, 2025, including 18 PPQ projects and 1 commercial project.Customer base expanded to more than 640 customers, with 14 of top 20 global pharmaceutical companies selecting WuXi XDC as a partner.Manufacturing footprint broadened across China, with Singapore site expected to achieve GMP release in H1 2026 under a global dual-sourcing strategy.R&D platform push continued, with focus on proprietary conjugation, linker, and payload-linker technologies including WuXiDARx, X-LinC, and WuXiTecan-2.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuxi XDC ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nNDL1cMyvN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823426480.USD","BK1576","LU0327786744.USD","LU1794554557.SGD","LU0417516902.SGD","LU1720050803.USD","LU0572944931.SGD","SG9999014674.SGD","LU0052750758.USD","LU0516423091.SGD","LU0979878070.USD","LU0140636845.USD","LU0856984785.SGD","LU0819121731.USD","LU1688375341.USD","LU0417516738.SGD","LU0181495838.USD","LU0320764599.SGD","02269","IE00B0JY6N72.USD","LU2039709279.SGD","LU0823426308.USD","LU1880383366.USD","LU0456846285.SGD","LU0039217434.USD","LU0348825331.USD","SG9999002562.SGD","SG9999002463.SGD","LU0326950275.SGD","LU0307460666.USD","BK1141","LU3063872942.SGD","LU0588546209.SGD","LU0456827905.SGD","LU0043850808.USD","LU2488822045.USD","LU0359201612.USD","LU0708995583.HKD","LU0516422952.EUR","LU0516422440.USD","LU0051755006.USD","LU1242518931.SGD","BK1589","LU0516422366.SGD","LU0516423174.USD","LU1242518857.USD","02268","BK1610","LU0359202008.SGD","LU0348735423.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629081646","title":"Wuxi Biologics (Cayman) Stock Slides 1.2% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2629081646","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629081646?lang=en_us&edition=fundamental","pubTime":"2026-04-24 16:32","pubTimestamp":1777019520,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Wuxi Biologics  Inc. slipped 1.2% to 33.52 Hong Kong dollars on what proved to be an all-around favorable trading session for the Hong Kong stock market, with the Hang Seng Index rising 0.2% to 25978.07.This was the stock's sixth consecutive day of losses.Wuxi Biologics  Inc. closed 24% below its 52-week high of HK$44.00, which the company reached Feb. 12.Trading volume totaled 23.4 million shares, compared to the 50-day average of 30.1 million shares.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0516423174.USD","LU0823426480.USD","LU0359202008.SGD","LU0516423091.SGD","LU1242518857.USD","LU0051755006.USD","LU0052750758.USD","SG9999002562.SGD","LU1688375341.USD","LU0516422952.EUR","BK1576","LU2039709279.SGD","BK1589","LU0456846285.SGD","LU0417516902.SGD","LU0456827905.SGD","LU0320764599.SGD","LU0708995583.HKD","LU1242518931.SGD","LU0516422440.USD","LU0819121731.USD","LU0979878070.USD","LU0588546209.SGD","LU0327786744.USD","LU0181495838.USD","LU0039217434.USD","LU0326950275.SGD","LU0572944931.SGD","LU1794554557.SGD","LU0043850808.USD","LU0417516738.SGD","BK1610","LU0348735423.USD","IE00B0JY6N72.USD","LU0823426308.USD","LU0307460666.USD","BK1521","LU0856984785.SGD","LU3063872942.SGD","SG9999002463.SGD","LU0359201612.USD","LU0140636845.USD","LU0348825331.USD","LU1720050803.USD","LU0516422366.SGD","02269","LU1880383366.USD","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629886637","title":"Wuxi Biologics (Cayman) Stock Sheds 3.1% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2629886637","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629886637?lang=en_us&edition=fundamental","pubTime":"2026-04-23 16:31","pubTimestamp":1776933060,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Wuxi Biologics  Inc. shed 3.1% to 33.92 Hong Kong dollars on what proved to be an all-around poor trading session for the Hong Kong stock market, with the Hang Seng Index falling 0.9% to 25915.20.This was the stock's fifth consecutive day of losses.Wuxi Biologics  Inc. closed 23% short of its 52-week high of HK$44.00, which the company achieved Feb. 12.Trading volume totaled 25.3 million shares, compared to the 50-day average of 30.1 million shares.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0043850808.USD","LU0708995583.HKD","LU1688375341.USD","LU0039217434.USD","LU0181495838.USD","LU1720050803.USD","LU1242518931.SGD","LU0516422440.USD","LU3063872942.SGD","LU0052750758.USD","LU0326950275.SGD","LU0516422952.EUR","LU0516423091.SGD","LU0051755006.USD","SG9999002463.SGD","BK1141","LU0588546209.SGD","LU0320764599.SGD","LU0417516738.SGD","BK1589","LU0359202008.SGD","BK1610","LU0307460666.USD","LU1794554557.SGD","LU0348735423.USD","SG9999002562.SGD","LU0456827905.SGD","LU0979878070.USD","BK1576","BK1521","LU0348825331.USD","LU0856984785.SGD","LU0327786744.USD","LU2039709279.SGD","LU0140636845.USD","LU0417516902.SGD","LU0359201612.USD","LU0823426308.USD","LU0572944931.SGD","LU0823426480.USD","LU0819121731.USD","LU1242518857.USD","LU1880383366.USD","02269","LU0516423174.USD","IE00B0JY6N72.USD","LU0516422366.SGD","LU0456846285.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629002740","title":"WuXi Biologics wins South Korea MFDS GMP certification for three Wuxi facilities","url":"https://stock-news.laohu8.com/highlight/detail?id=2629002740","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629002740?lang=en_us&edition=fundamental","pubTime":"2026-04-23 14:17","pubTimestamp":1776925048,"startTime":"0","endTime":"0","summary":"WuXi Biologics secured GMP certification from South Korea MFDS for three Wuxi manufacturing sites.Certification supports end-to-end commercial manufacturing for a bispecific antibody targeting biliary tract cancer.MFDS inspection reported no critical or major findings across the facilities.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nNDL38hjxw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1521","LU0417516902.SGD","LU0348825331.USD","LU0348735423.USD","BK1141","LU0979878070.USD","LU2039709279.SGD","LU0516423174.USD","BK1610","LU0516423091.SGD","LU0320764599.SGD","LU0456846285.SGD","LU0708995583.HKD","SG9999002562.SGD","LU0516422366.SGD","LU0307460666.USD","LU0516422440.USD","LU0456827905.SGD","LU0039217434.USD","LU1794554557.SGD","LU1242518931.SGD","LU0359201612.USD","LU0856984785.SGD","LU1242518857.USD","SG9999002463.SGD","LU1720050803.USD","LU0326950275.SGD","LU0359202008.SGD","LU1880383366.USD","LU0140636845.USD","LU0051755006.USD","LU1688375341.USD","LU0043850808.USD","LU0819121731.USD","LU0417516738.SGD","LU0327786744.USD","02269","LU0823426308.USD","LU0823426480.USD","BK1589","LU0516422952.EUR","LU0572944931.SGD","LU0052750758.USD","LU0181495838.USD","BK1576","LU3063872942.SGD","LU0588546209.SGD","IE00B0JY6N72.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165196464","title":"HK Biotech Stocks Fell. Akeso Down 12%; Remegen, Zai Lab, KeyMed And Junshi Down 7%; Lepu And Innocare Down 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1165196464","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165196464?lang=en_us&edition=fundamental","pubTime":"2026-04-23 11:32","pubTimestamp":1776915127,"startTime":"0","endTime":"0","summary":"HK biotech stocks fell. Akeso down 12%; Remegen, Zai Lab, KeyMed and Junshi down 7%; Lepu and Innocare down 6%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"330240692f324d079ccf839d9e4180bf","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978","02137","01672","06606","09966","02269","09926","09995","02162","03759","03347","02359","02268","09606","09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628527918","title":"Wuxi Biologics (Cayman) Stock Slides 3.9% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2628527918","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628527918?lang=en_us&edition=fundamental","pubTime":"2026-04-17 16:31","pubTimestamp":1776414660,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Wuxi Biologics  Inc. shed 3.9% to 35.72 Hong Kong dollars on what proved to be an all-around dismal trading session for the Hong Kong stock market, with the Hang Seng Index falling 0.9% to 26160.33.Wuxi Biologics  Inc. closed 19% below its 52-week high of HK$44.00, which the company reached Feb. 12.Trading volume totaled 31.2 million shares, compared to the 50-day average of 31.3 million shares.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999002463.SGD","LU1688375341.USD","LU0708995583.HKD","LU1242518857.USD","BK1141","LU0039217434.USD","LU0051755006.USD","LU0572944931.SGD","LU0823426480.USD","LU0417516902.SGD","LU1720050803.USD","LU0588546209.SGD","BK1589","LU1242518931.SGD","LU0823426308.USD","LU0516423091.SGD","LU0456846285.SGD","LU0348735423.USD","LU0819121731.USD","SG9999002562.SGD","LU0326950275.SGD","BK1521","LU0456827905.SGD","LU0359202008.SGD","LU0043850808.USD","LU0359201612.USD","LU0856984785.SGD","IE00B0JY6N72.USD","LU0516422952.EUR","LU0320764599.SGD","LU0516422366.SGD","LU0417516738.SGD","02269","BK1576","LU0979878070.USD","LU0140636845.USD","LU1880383366.USD","LU0516423174.USD","LU2039709279.SGD","LU0052750758.USD","LU0181495838.USD","LU0327786744.USD","LU0348825331.USD","LU3063872942.SGD","LU0516422440.USD","BK1610","LU1794554557.SGD","LU0307460666.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628322752","title":"WuXi Biologics named Morningstar Sustainalytics industry, regional ESG leader for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2628322752","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628322752?lang=en_us&edition=fundamental","pubTime":"2026-04-17 13:31","pubTimestamp":1776403893,"startTime":"0","endTime":"0","summary":"WuXi Biologics was named Morningstar Sustainalytics Industry ESG Leader and Regional ESG Leader for 2026.Recognition marked sixth consecutive year of ESG Leader distinction for WuXi Biologics.Sustainalytics said its 2026 ESG Risk Ratings assessed about 15,000 companies across 42 industries.WuXi Biologics said it ranked in top 1% globally for ESG risk score in July 2025, reaching negligible-risk tier.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nNDL786ybx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","LU0516422952.EUR","LU0588546209.SGD","LU0417516738.SGD","LU1688375341.USD","LU0348825331.USD","LU0856984785.SGD","LU1242518857.USD","LU0979878070.USD","LU1880383366.USD","LU0348735423.USD","LU0326950275.SGD","BK1576","LU0052750758.USD","LU0516423174.USD","LU3063872942.SGD","SG9999002562.SGD","LU1242518931.SGD","LU0181495838.USD","LU0516423091.SGD","LU0516422366.SGD","LU0140636845.USD","LU0359201612.USD","LU0039217434.USD","BK1521","LU0456846285.SGD","LU0327786744.USD","LU0456827905.SGD","LU2039709279.SGD","02269","BK1610","IE00B0JY6N72.USD","LU1794554557.SGD","LU0516422440.USD","LU0708995583.HKD","LU1720050803.USD","LU0320764599.SGD","SG9999002463.SGD","LU0051755006.USD","LU0572944931.SGD","LU0043850808.USD","LU0359202008.SGD","LU0417516902.SGD","LU0823426308.USD","LU0307460666.USD","LU0823426480.USD","LU0819121731.USD","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628243499","title":"A Look At WuXi Biologics (SEHK:2269) Valuation After Securing ISO 13485:2016 Certification","url":"https://stock-news.laohu8.com/highlight/detail?id=2628243499","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628243499?lang=en_us&edition=fundamental","pubTime":"2026-04-17 01:08","pubTimestamp":1776359316,"startTime":"0","endTime":"0","summary":"WuXi Biologics (Cayman) (SEHK:2269) recently obtained ISO 13485:2016 certification for its medical device quality management system with zero non conformities, an event that draws attention to how quality and compliance feed into its equity story.\nSee our latest analysis for WuXi Biologics (Cayman).\nThe ISO 13485:2016 win comes as the share price trades at HK$37.18, with a 1 month share price return of 6.41% and a year to date share price return of 14.26%. Over a longer horizon, the 1 year...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2269/wuxi-biologics-cayman-shares/news/a-look-at-wuxi-biologics-sehk2269-valuation-after-securing-i","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2269/wuxi-biologics-cayman-shares/news/a-look-at-wuxi-biologics-sehk2269-valuation-after-securing-i","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0043850808.USD","LU0708995583.HKD","LU1688375341.USD","LU0039217434.USD","LU0181495838.USD","LU1720050803.USD","LU1242518931.SGD","LU0516422440.USD","LU3063872942.SGD","LU0052750758.USD","ISO","LU0326950275.SGD","LU0516422952.EUR","LU0516423091.SGD","LU0051755006.USD","SG9999002463.SGD","BK1141","LU0588546209.SGD","LU0320764599.SGD","LU0417516738.SGD","BK1589","LU0359202008.SGD","BK1610","LU0307460666.USD","LU1794554557.SGD","LU0348735423.USD","SG9999002562.SGD","LU0456827905.SGD","LU0979878070.USD","BK1576","BK1521","LU0348825331.USD","LU0856984785.SGD","LU0327786744.USD","LU2039709279.SGD","LU0140636845.USD","LU0417516902.SGD","BK4121","LU0359201612.USD","LU0823426308.USD","LU0572944931.SGD","LU0823426480.USD","LU0819121731.USD","LU1242518857.USD","LU1880383366.USD","02269","LU0516423174.USD","IE00B0JY6N72.USD","LU0516422366.SGD","LU0456846285.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627471217","title":"WuXi Biologics wins ISO 13485:2016 certification for drug-device combination products","url":"https://stock-news.laohu8.com/highlight/detail?id=2627471217","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627471217?lang=en_us&edition=fundamental","pubTime":"2026-04-15 10:40","pubTimestamp":1776220858,"startTime":"0","endTime":"0","summary":"WuXi Biologics secured ISO 13485:2016 certification for its medical device quality management system, supporting drug-device combination product development and manufacturing.Audit recorded zero non-conformities, strengthening WuXi Biologics’ compliance position for commercial-scale combination-product manufacturing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuxi Biologics  Inc. published the original content used to generate this news brief via PR Newswire  on April 15, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nNDL5KV1H5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269","LU0359202008.SGD","LU0359201612.USD","BK1141","LU2039709279.SGD","LU0348825331.USD","BK1576","LU0979878070.USD","LU0181495838.USD","LU0140636845.USD","LU0320764599.SGD","LU0052750758.USD","LU0348735423.USD","LU0043850808.USD","LU1242518931.SGD","SG9999002463.SGD","LU0456827905.SGD","LU0516422952.EUR","IE00B0JY6N72.USD","LU0708995583.HKD","LU0516423091.SGD","LU0516422440.USD","LU0039217434.USD","LU1794554557.SGD","LU0307460666.USD","LU0417516902.SGD","LU1880383366.USD","LU0588546209.SGD","LU0327786744.USD","LU0516423174.USD","LU0516422366.SGD","LU1688375341.USD","LU0823426480.USD","LU0326950275.SGD","BK1610","LU0417516738.SGD","LU0051755006.USD","LU0856984785.SGD","BK1589","LU0456846285.SGD","LU3063872942.SGD","LU1242518857.USD","LU0572944931.SGD","SG9999002562.SGD","BK1521","LU1720050803.USD","LU0819121731.USD","LU0823426308.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152234148","title":"Pharmaceutical Innovation Sector Gains Policy Support as State Council Issues Guidelines on Drug Pricing Mechanisms (With Relevant Stocks)","url":"https://stock-news.laohu8.com/highlight/detail?id=1152234148","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152234148?lang=en_us&edition=fundamental","pubTime":"2026-04-15 07:24","pubTimestamp":1776209091,"startTime":"0","endTime":"0","summary":"A new policy document issued by the State Council aims to improve the market-based drug pricing mechanism, with significant positive implications for the innovative drug sector. The guidelines...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0588546209.SGD","LU1242518857.USD","LU0348825331.USD","LU2242644610.SGD","LU0417516738.SGD","LU0051755006.USD","LU0307460666.USD","02315","BK1610","06127","IE00B0JY6N72.USD","LU0181495838.USD","LU1046422090.SGD","LU2125910500.SGD","LU0456827905.SGD","LU0516423091.SGD","LU0708995583.HKD","LU0516422366.SGD","LU0856984785.SGD","LU0359201612.USD","BK1141","VXUS","BK1576","LU2045819591.USD","159992","LU0819121731.USD","02269","LU0979878070.USD","LU0327786744.USD","LU0572944931.SGD","LU0039217434.USD","LU0516422952.EUR","BK4585","LU0417516902.SGD","LU0516422440.USD","LU0320764599.SGD","LU1794554557.SGD","SG9999002562.SGD","06978","LU1880383366.USD","LU3063872942.SGD","BK1574","LU2039709279.SGD","LU0823426308.USD","BK1583","03347","BK1161","LU0456846285.SGD","LU0516423174.USD","SG9999002463.SGD","LU1242518931.SGD","LU0348735423.USD","LU0052750758.USD","LU0823426480.USD","02359","LU0359202008.SGD","LU0043850808.USD","LU1688375341.USD","LU0140636845.USD","BK4588","BK1521","BK1589","LU1720050803.USD","LU0326950275.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627433977","title":"Wuxi Biologics (Cayman) Stock Falls 1.7% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2627433977","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627433977?lang=en_us&edition=fundamental","pubTime":"2026-04-13 16:33","pubTimestamp":1776069180,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Wuxi Biologics  Inc. slipped 1.7% to 35.28 Hong Kong dollars on what proved to be an all-around dismal trading session for the Hong Kong stock market, with the Hang Seng Index falling 0.9% to 25660.85.The stock's fall snapped a six-day winning streak.Wuxi Biologics  Inc. closed 20% below its 52-week high of HK$44.00, which the company achieved Feb. 12.Trading volume totaled 14.7 million shares, compared to the 50-day average of 31.8 million shares.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0856984785.SGD","LU3063872942.SGD","LU0181495838.USD","LU0348825331.USD","LU0516422440.USD","BK1589","BK1576","LU0359201612.USD","LU0359202008.SGD","SG9999002463.SGD","LU0327786744.USD","LU1242518931.SGD","LU1720050803.USD","LU2039709279.SGD","BK1141","LU0140636845.USD","LU0417516738.SGD","LU0823426480.USD","LU0320764599.SGD","LU0979878070.USD","LU0039217434.USD","IE00B0JY6N72.USD","LU0326950275.SGD","LU0708995583.HKD","LU0516423174.USD","LU1688375341.USD","LU0307460666.USD","LU0516422366.SGD","LU0823426308.USD","LU0456846285.SGD","LU0819121731.USD","LU1880383366.USD","LU0588546209.SGD","LU0043850808.USD","LU0456827905.SGD","LU0572944931.SGD","LU1794554557.SGD","LU0516422952.EUR","02269","LU0052750758.USD","LU0348735423.USD","LU0417516902.SGD","BK1521","LU1242518857.USD","SG9999002562.SGD","LU0051755006.USD","BK1610","LU0516423091.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626820198","title":"Wuxi Biologics (Cayman) Stock Climbs 1.0% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2626820198","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626820198?lang=en_us&edition=fundamental","pubTime":"2026-04-10 16:33","pubTimestamp":1775809980,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Wuxi Biologics  Inc. rose 1.0% to 35.90 Hong Kong dollars on what proved to be an all-around great trading session for the Hong Kong stock market, with the Hang Seng Index rising 0.5% to 25893.54.This was the stock's sixth consecutive day of gains.Wuxi Biologics  Inc. closed 18% short of its 52-week high of HK$44.00, which the company reached Feb. 12.Trading volume totaled 19.4 million shares, compared to the 50-day average of 32.1 million shares.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0417516902.SGD","BK1521","LU2039709279.SGD","LU0456846285.SGD","SG9999002562.SGD","LU0516422366.SGD","LU0516422440.USD","BK1589","LU0140636845.USD","LU0823426480.USD","LU0516422952.EUR","LU1688375341.USD","IE00B0JY6N72.USD","LU0588546209.SGD","BK1576","LU0326950275.SGD","LU0348735423.USD","LU0708995583.HKD","LU0051755006.USD","LU1794554557.SGD","LU3063872942.SGD","BK1610","LU0052750758.USD","LU0043850808.USD","BK1141","LU0456827905.SGD","LU0856984785.SGD","LU0039217434.USD","LU0359201612.USD","LU0181495838.USD","LU0516423091.SGD","LU1880383366.USD","LU1242518857.USD","02269","LU0516423174.USD","LU0307460666.USD","LU0327786744.USD","LU0320764599.SGD","LU0417516738.SGD","LU0348825331.USD","LU0572944931.SGD","LU0819121731.USD","LU0979878070.USD","LU1720050803.USD","LU1242518931.SGD","SG9999002463.SGD","LU0359202008.SGD","LU0823426308.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626878571","title":"Akari CEO says WuXi XDC partnership accelerates AKTX-101 IND toward late 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2626878571","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626878571?lang=en_us&edition=fundamental","pubTime":"2026-04-09 20:54","pubTimestamp":1775739282,"startTime":"0","endTime":"0","summary":"Akari CEO Abizer Gaslightwala outlined strategic partnership with WuXi XDC in a Virtual Investor “What This Means” interview.Gaslightwala framed partnership as validation of Akari PH1 spliceosome-modulating payload platform for antibody-drug conjugates.Management expects collaboration to accelerate lead program AKTX-101 toward an IND filing in late 2026.Interview described deal as extending beyond a standard contract manufacturer relationship, aiming to reduce development execution risk.Akari positioned partnership as strengthening its footing in a more active ADC deal market.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief on April 09, 2026, and is s","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDL3M7MKj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0181495838.USD","LU0516422366.SGD","BK4007","LU1242518931.SGD","LU0417516902.SGD","LU0856984785.SGD","BK4139","LU0348825331.USD","SG9999002562.SGD","LU0516423174.USD","LU2039709279.SGD","LU0359202008.SGD","BK1141","AKTX","IE00B0JY6N72.USD","LU0327786744.USD","LU0320764599.SGD","LU0708995583.HKD","SG9999014674.SGD","02268","LU0456827905.SGD","LU0819121731.USD","LU0823426480.USD","LU0516423091.SGD","LU0140636845.USD","LU1242518857.USD","LU0326950275.SGD","LU0043850808.USD","LU0307460666.USD","LU0417516738.SGD","LU0979878070.USD","BK1521","LU1688375341.USD","BK1610","SG9999002463.SGD","LU0516422440.USD","LU1794554557.SGD","LU1880383366.USD","LU3063872942.SGD","02269","LU0456846285.SGD","LU0348735423.USD","LU0588546209.SGD","LU2488822045.USD","LU0051755006.USD","LU0052750758.USD","LU0572944931.SGD","LU0359201612.USD","LU0516422952.EUR","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147398971","title":"WUXI BIO Issues 0.25 Million New Shares via Option Exercises, Expanding Total Share Capital to 4.14 Billion in March 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1147398971","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147398971?lang=en_us&edition=fundamental","pubTime":"2026-04-09 16:41","pubTimestamp":1775724108,"startTime":"0","endTime":"0","summary":"WuXi Biologics (Cayman) Inc. released its March 2026 monthly return, detailing incremental yet notable movements in share capital. The authorised share capital remained unchanged at 6.00 billion...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122102811","title":"HK Movers | Pharmaceutical Stocks Rally With Joinn up 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1122102811","media":"Tiger Newspress","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122102811?lang=en_us&edition=fundamental","pubTime":"2026-04-09 09:49","pubTimestamp":1775699344,"startTime":"0","endTime":"0","summary":"Pharmaceutical stocks rallied in Hong Kong. $Joinn(06127)$ rose 7%; $Asymchem(06821)$ and $Pharmaron(03759)$ rose 4%; $WuXi AppTec(02359)$, $Genscript Biotech(01548)$, and $Tigermed(03347)$ rose 3%; $WuXi Biologics(02269)$ rose 2%.   ","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"856cdb69403d887dc4a082d3a2a26688","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02359","06127","01548","06821","02269","03759","03347"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625941077","title":"WuXi XDC files HKEX next-day return, issues 1,507,353 shares at HKD 1.8-7.5","url":"https://stock-news.laohu8.com/highlight/detail?id=2625941077","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625941077?lang=en_us&edition=fundamental","pubTime":"2026-04-08 21:01","pubTimestamp":1775653289,"startTime":"0","endTime":"0","summary":"WuXi XDC filed a next-day disclosure return showing issuance of 1,507,353 new ordinary shares via employee share option exercises between April 1 and April 8.Issue prices ranged from HKD 1.80 to HKD 7.50 per share.Issued shares rose to 1,260,343,250 as of April 8 from 1,258,835,897 on March 31.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuxi XDC Cayman Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 08, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDL3gHWCr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269","LU0819121731.USD","LU0516423091.SGD","LU1880383366.USD","LU0327786744.USD","IE00B0JY6N72.USD","LU0823426308.USD","LU0051755006.USD","SG9999014674.SGD","LU0043850808.USD","LU0348825331.USD","LU0856984785.SGD","LU0516422952.EUR","LU0823426480.USD","LU0140636845.USD","LU0417516738.SGD","LU0979878070.USD","LU0516423174.USD","LU1794554557.SGD","BK1521","LU0359201612.USD","LU0456846285.SGD","LU2488822045.USD","LU0181495838.USD","LU1242518931.SGD","LU0359202008.SGD","LU0052750758.USD","LU0588546209.SGD","LU2039709279.SGD","LU3063872942.SGD","BK1610","LU0320764599.SGD","LU0326950275.SGD","LU0039217434.USD","LU0456827905.SGD","LU1688375341.USD","LU0572944931.SGD","LU0516422366.SGD","LU0417516902.SGD","LU1720050803.USD","BK1589","BK1141","02268","LU0348735423.USD","SG9999002463.SGD","LU0307460666.USD","LU0708995583.HKD","LU1242518857.USD","SG9999002562.SGD","LU0516422440.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625411529","title":"WuXi XDC grants 4,854,500 nil-cost restricted shares under 2024 scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=2625411529","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625411529?lang=en_us&edition=fundamental","pubTime":"2026-04-08 20:55","pubTimestamp":1775652934,"startTime":"0","endTime":"0","summary":"WuXi XDC granted 4,854,500 restricted shares under its 2024 share scheme on April 8, 2026.Awards went to 425 grantees, including 3 executive directors.Purchase price set at nil; shares closed at HK$ 60.65 on grant date.Vesting set at 25% on each anniversary of grant date.Directors received 364,200 restricted shares in total, including 155,300 to CEO Jincai Li.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuxi XDC Cayman Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 08, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDL1frDrv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0140636845.USD","LU0359201612.USD","LU0516422952.EUR","BK1589","LU0856984785.SGD","LU0181495838.USD","02268","LU0979878070.USD","LU0516423091.SGD","02269","LU0516423174.USD","LU0417516738.SGD","BK1610","LU1720050803.USD","LU0823426308.USD","LU0417516902.SGD","LU0819121731.USD","LU0823426480.USD","SG9999002562.SGD","LU0320764599.SGD","LU0456846285.SGD","LU1242518857.USD","LU0326950275.SGD","LU0307460666.USD","LU1688375341.USD","LU1794554557.SGD","LU0052750758.USD","BK1576","LU2488822045.USD","LU0516422440.USD","LU0516422366.SGD","LU0348825331.USD","BK1141","LU0043850808.USD","LU0456827905.SGD","LU0359202008.SGD","LU0039217434.USD","LU2039709279.SGD","LU1880383366.USD","LU0348735423.USD","SG9999014674.SGD","LU0572944931.SGD","IE00B0JY6N72.USD","LU0051755006.USD","SG9999002463.SGD","LU0327786744.USD","LU0708995583.HKD","LU3063872942.SGD","BK1521","LU0588546209.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625671117","title":"Akari partners with WuXi XDC to accelerate PH1 ADC payload development, IND by 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2625671117","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625671117?lang=en_us&edition=fundamental","pubTime":"2026-04-06 20:47","pubTimestamp":1775479679,"startTime":"0","endTime":"0","summary":"Akari Therapeutics entered strategic partnership with WuXi XDC to accelerate development of its PH1 antibody-drug conjugate payload targeting RNA splicing.Collaboration targets an IND filing by late 2026.Partnership supports lead program AKTX-101, initially aimed at metastatic urothelial cancer.Akari expects Phase 1 trial for AKTX-101 to start in late 2026 or early 2027, subject to regulatory clearance.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief on April 06, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nNDL3w1p7D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0043850808.USD","LU0708995583.HKD","LU1688375341.USD","BK4007","LU0039217434.USD","LU0181495838.USD","LU1720050803.USD","SG9999014674.SGD","LU1242518931.SGD","LU0516422440.USD","LU3063872942.SGD","BK4139","LU0326950275.SGD","LU0516422952.EUR","LU0516423091.SGD","LU0051755006.USD","SG9999002463.SGD","BK1141","LU0588546209.SGD","LU0320764599.SGD","LU0417516738.SGD","BK1589","LU0359202008.SGD","LU2488822045.USD","BK1610","LU1794554557.SGD","LU0348735423.USD","SG9999002562.SGD","LU0456827905.SGD","LU0979878070.USD","BK1576","BK1521","LU0348825331.USD","LU0856984785.SGD","02268","LU0140636845.USD","LU0417516902.SGD","LU0359201612.USD","LU0823426308.USD","LU0572944931.SGD","LU0823426480.USD","LU0819121731.USD","LU1242518857.USD","AKTX","LU1880383366.USD","02269","LU0516423174.USD","IE00B0JY6N72.USD","LU0516422366.SGD","LU0456846285.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624369573","title":"WuXi Biologics publishes 2025 annual report, revenue rises 16.7% to RMB 21,790 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624369573","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624369573?lang=en_us&edition=fundamental","pubTime":"2026-04-02 14:35","pubTimestamp":1775111748,"startTime":"0","endTime":"0","summary":"WuXi Biologics published its 2025 annual report, citing robust growth driven by its integrated end-to-end CRDMO platform and “Follow and Win the Molecule” strategy.Project pipeline expanded with 209 new integrated projects, lifting total ongoing integrated projects to 945.Late-stage mix increased with 74 late-phase projects, supported by 25 commercial manufacturing projects.Backlog rose to USD 23.7 billion, including USD 11.5 billion in service backlog.Board did not recommend a final dividend for year ended Dec. 31, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuxi Biologics  Inc. published the original content used to generate this news brief on April 02, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL1B9VZv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B0JY6N72.USD","LU0348825331.USD","LU1880383366.USD","LU0979878070.USD","LU0708995583.HKD","LU0516422952.EUR","LU0823426308.USD","LU0359202008.SGD","SG9999002463.SGD","LU0348735423.USD","02269","LU0516423091.SGD","LU0307460666.USD","BK1521","LU1720050803.USD","LU3063872942.SGD","LU1242518857.USD","BK1589","LU0181495838.USD","LU0572944931.SGD","LU0516423174.USD","LU0456827905.SGD","BK1576","LU0052750758.USD","LU0326950275.SGD","LU0516422440.USD","BK1610","LU0819121731.USD","LU0588546209.SGD","SG9999002562.SGD","LU0140636845.USD","BK1141","LU0823426480.USD","LU2039709279.SGD","LU1242518931.SGD","LU0039217434.USD","LU0043850808.USD","LU0327786744.USD","LU0516422366.SGD","LU1794554557.SGD","LU0417516738.SGD","LU0417516902.SGD","LU0456846285.SGD","LU1688375341.USD","LU0320764599.SGD","LU0856984785.SGD","LU0359201612.USD","LU0051755006.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.wuxibiologics.com","stockEarnings":[{"period":"1week","weight":-0.0646},{"period":"1month","weight":0.0284},{"period":"3month","weight":-0.127},{"period":"6month","weight":-0.0947},{"period":"1year","weight":0.4596},{"period":"ytd","weight":0.0585}],"compareEarnings":[{"period":"1week","weight":-0.0165},{"period":"1month","weight":0.039},{"period":"3month","weight":-0.0443},{"period":"6month","weight":-0.016},{"period":"1year","weight":0.1795},{"period":"ytd","weight":0.0115}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"WuXi Biologics (Cayman) Inc is an investment holding company principally engaged in the provision of end-to-end solutions and services for biologics discovery, development and manufacturing to customers involving in biologics industry. The Company mainly operates its business through two segments. The Biologics segment mainly engages in the provision of biologics discovery, development and manufacturing. The WuXi XDC (XDC) segment mainly engages in the provision of contract research, development and manufacturing organization (CRDMO) services for antibody-drug conjugate (ADCs) and various bioconjugates. The Company mainly conducts its business in the domestic and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.777778,"avgChangeRate":0.052868},{"month":2,"riseRate":0.555556,"avgChangeRate":0.006907},{"month":3,"riseRate":0.555556,"avgChangeRate":-0.001977},{"month":4,"riseRate":0.444444,"avgChangeRate":0.000319},{"month":5,"riseRate":0.5,"avgChangeRate":0.00166},{"month":6,"riseRate":0.625,"avgChangeRate":0.064583},{"month":7,"riseRate":0.666667,"avgChangeRate":0.081469},{"month":8,"riseRate":0.555556,"avgChangeRate":0.030253},{"month":9,"riseRate":0.666667,"avgChangeRate":0.056337},{"month":10,"riseRate":0.444444,"avgChangeRate":-0.033632},{"month":11,"riseRate":0.444444,"avgChangeRate":0.025584},{"month":12,"riseRate":0.555556,"avgChangeRate":0.009161}],"exchange":"SEHK","name":"WUXI BIO","nameEN":"WUXI BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"WUXI BIO(02269),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest WUXI BIO(02269) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"WUXI BIO,02269,WUXI BIO股票,WUXI BIO股票老虎,WUXI BIO股票老虎国际,WUXI BIO行情,WUXI BIO股票行情,WUXI BIO股价,WUXI BIO股市,WUXI BIO股票价格,WUXI BIO股票交易,WUXI BIO股票购买,WUXI BIO股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"WUXI BIO(02269),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest WUXI BIO(02269) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}